Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Alliance Pharma ( (GB:APH) ) has shared an announcement.
Alliance Pharma reported a 1% decline in see-through revenues to £180.3m for the year ended December 31, 2024, with a constant exchange rate increase of 1%. Despite challenges in some brands, the company saw strong performances from Kelo-Cote, MacuShield, Hydromol, and Forceval. While Kelo-Cote revenues grew by 6%, Nizoral and Amberen experienced declines. Prescription Medicine revenues increased by 8%, contributing to the strong performance in the sector. The company anticipates underlying Group profit for FY 2024 to align with FY 2023, with CEO Nick Sedgwick expressing confidence in the long-term organic growth of their brand portfolio.
More about Alliance Pharma
Alliance Pharma plc is a growing consumer healthcare company headquartered in the UK. The company aims to empower people to improve their health and wellbeing through its trusted and proven brands, available worldwide. Alliance Pharma focuses on organic growth by investing in priority brands and channels, related innovation, and selective geographic expansion. The company employs around 285 people across Europe, North America, and the Asia Pacific region and remains asset-light by outsourcing manufacturing and logistics.
YTD Price Performance: 33.55%
Average Trading Volume: 3,215,536
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £330.3M
Learn more about APH stock on TipRanks’ Stock Analysis page.
